AstraZeneca PLC (AZN) Balance Sheet

The equity build is driven by retained earnings, which surged from -$212M in 2024Q1 to $12.6B in 2026Q2, reflecting robust profitability and disciplined capital allocation. Total liabilities have remained relatively stable around $65B, suggesting that the company is not aggressively levering up to fund growth. This trajectory implies that AstraZeneca is generating sufficient internal capital to support its expansion, reducing reliance on external financing.

The D/E ratio has declined steadily over the past two years, driven by both equity growth and a reduction in absolute debt from $34.6B to $32.2B. This suggests that the company is managing its leverage prudently, likely using cash flows to pay down debt. The current leverage level is moderate compared to peers like BMY (2.55) and LLY (1.60), indicating a comfortable debt load that does not appear to constrain strategic flexibility.

The significant rise in PPE suggests a major capital expenditure phase, consistent with the capex spike noted in the cash flow analysis. This investment likely supports manufacturing expansion for biologics and rare disease therapies, which could enhance long-term margin stability. Goodwill has remained flat, implying no major impairment concerns, but investors should monitor whether the increased PPE yields expected returns.

The dramatic improvement in retained earnings underscores the company's ability to generate and retain profits, which is a hallmark of high-quality equity. This accumulation provides a buffer against future shocks and supports ongoing dividend payments, which have been substantial. The equity base is now more resilient, reducing the risk of dilution or the need for external capital.

The current ratio has consistently remained below 1.0 over the past ten quarters, suggesting that current liabilities exceed current assets. However, this is common in large pharma where cash generation is strong and short-term debt is manageable. The cash position of $4.9B, while lower than prior quarters, is supplemented by robust operating cash flows, which averaged over $4B per quarter, providing adequate liquidity to meet near-term obligations.